Critical Outcome Technologies Inc.: Promising Advance for Many Common Cancers
COTI-2 demonstrates activity against many common p53 gene mutations
(firmenpresse) - LONDON, ONTARIO -- (Marketwired) -- 06/11/13 -- Critical Outcome Technologies Inc. (TSX VENTURE: COT) ("COTI" or the "Corporation") announces positive results from experiments carried out with its lead cancer drug candidate, COTI-2, in the cancer research laboratories of Gordon Mills, M.D., Ph.D. Chair of the Department of Systems Biology and the Co-director of the Khalifa Institute for Personalized Cancer Therapy at The University of Texas MD Anderson Cancer Center in Houston, Texas. These preclinical experiments were designed to definitively determine the effect of COTI-2 in 32 common p53 mutations. The p53 gene is a tumor suppressing gene. However, if the p53 gene is mutated, cancers often develop and grow out of control.
"These results are encouraging given the central importance of p53 gene mutations in many cancers," stated Dr. Mills. "Our research and data confirm that COTI-2 is most active in mutant p53 tumors and the effect of COTI-2 in many specific p53 mutations is striking. In addition, it appears that this effect can be augmented by the presence of mutations in the AKT signaling pathway. The preclinical data with COTI-2 in cell lines, animal models and the potential mechanism of action warrant clinical trials. These clinical trials should evaluate both response and the utility of biomarkers to select patients. If COTI-2 proves to be highly active in people with p53 mutant tumors, this would represent a breakthrough therapy for many cancer patients."
"New therapies that target mutations of genes such as p53 represent a promising approach compared to conventional organ-specific cancer treatments," said Dr. Wayne Danter, COTI's CEO. "These important results confirm and extend our understanding of the mechanism of action ("MOA") of COTI-2. While previous internal research indicated that COTI-2's effectiveness was related to the p53 mutation status of the tumor, the quality and amount of scientific data provided by Dr. Mills are definitive and answer the remaining MOA questions posed by potential licensing partners who are waiting for these results."
Extensive data from the experiments have demonstrated that:
Other COTI-2 highlights:
About p53 gene mutations:
Mutations of the p53 gene are the most common genetic alterations in human cancers, occurring in:
About Critical Outcome Technologies Inc. (COTI)
COTI is a leading-edge technology company specializing in accelerating the discovery and development of small molecules - dramatically reducing the time and cost to bring new drugs to market. COTI'S proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.
For more information, visit .
Follow (at)CriticalOutcome on Twitter at .
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
519-858-5157
Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 11.06.2013 - 11:00 Uhr
Sprache: Deutsch
News-ID 268391
Anzahl Zeichen: 0
contact information:
Town:
LONDON, ONTARIO
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 161 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Critical Outcome Technologies Inc.: Promising Advance for Many Common Cancers"
steht unter der journalistisch-redaktionellen Verantwortung von
Critical Outcome Technologies Inc. (COTI) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
